clene nanomedicine
-
AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA]…
-
CLENE ANNOUNCES STATISTICALLY SIGNIFICANT ALS BIOMARKER RESULTS SUPPORTING ACCELERATED APPROVAL PATHWAY FOR CNM-AU8®
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8.
-
CLENE PROVIDES UPDATE ON ITS NIH-FUNDED EXPANDED ACCESS PROGRAM FOR CNM-AU8® IN ALS (ACT-EAP)
First patient, first visit is planned for early June 2024
-
Clene Inc. Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting…
-
CLENE ANNOUNCES PUBLICATION OF PHASE 2 CNM-AU8® CLINICAL DATA FOR THE TREATMENT OF ALS IN LANCET’S ECLINICALMEDICINE
Peer-reviewed publication includes data from the CNM-Au8 Phase 2 RESCUE-ALS trial and its open-label-extension, up to 120 weeks…
-
Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
Clene announced that it has entered into a securities purchase agreement with certain existing stockholders.
-
Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24…
-
Updated Interim Data from Clene Nanomedicine’s RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting
Results show significant survival benefit in participants who entered open-label extension of study of CNM-Au8®, a gold nanocrystal…
-
Clene Nanomedicine’s Patent Portfolio Grows to More Than 150 Issued Worldwide, including Two Key Patents Now Validated Across Europe
Powerful combination of key patents comes as the Company looks ahead to topline results from a Phase 3…
-
Clene Nanomedicine to Present RESCUE-ALS Phase 2 Data in Late-Breaking Session at 32nd International Symposium on ALS/MND
Clene presented data from the RESCUE-ALS Phase 2 study of CNM-Au8®, a catalytically active gold nanocrystal suspension, for…
-
Clene Nanomedicine Announces Top-Line Results from Phase 2 RESCUE-ALS Clinical Trial
Clene recently announced top-line data from RESCUE-ALS, a Phase 2 clinical trial evaluating CNM-Au8 as a disease modifying…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
